Welcome to our dedicated page for Gain Therapeutics SEC filings (Ticker: GANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Gain Therapeutics’ latest 10-K can feel like decoding protein structures—dense science, layered risk factors and critical cash-runway data buried in footnotes. Whether you need the lab-by-lab R&D spend or want to see how a fresh licensing deal affects dilution, the company’s biotech disclosures demand time most investors don’t have.
Stock Titan delivers the antidote. Our AI parses every Gain Therapeutics SEC filing the moment it hits EDGAR—annual report 10-K simplified, quarterly earnings report 10-Q filing with expense and trial-cost breakdowns, and Form 4 insider transactions real-time. You’ll receive concise plain-English summaries, red-flag risk alerts and searchable tables, turning “understanding Gain Therapeutics SEC documents with AI” from wishful thinking into a three-click reality. Need to track a sudden management share purchase? Our dashboard surfaces Gain Therapeutics insider trading Form 4 transactions alongside executive stock transactions Form 4 history. Curious about board pay? The Gain Therapeutics proxy statement executive compensation section is highlighted and linked.
Investors use these insights to:
- Gauge cash burn and runway before phase-two readouts
- Monitor 8-K material events explained—trial milestones, financing rounds, or FDA feedback
- Compare segment expenses across quarters through Gain Therapeutics earnings report filing analysis
Gain Therapeutics reported operating losses and tightened liquidity in the first half of 2025 while continuing clinical development of its lead program. For the six months ended June 30, 2025 the company recorded a $10.34 million net loss, with total operating expenses of $9.46 million. Cash and cash equivalents were $6.69 million at June 30, 2025, down from $10.39 million at year-end 2024, and total assets were $9.83 million versus total liabilities of $6.14 million, leaving stockholders' equity of $3.70 million.
The company disclosed a going concern assessment, stating its June 30, 2025 cash is insufficient to fund operations for 12 months and that it will need additional capital to continue beyond Q1 2026. Management noted recent financings including ATM sales and a July 2025 public offering that generated net proceeds (July offering net proceeds of $6.1 million plus an additional $1.0 million from over-allotment) and described actions to optimize costs and pursue collaborations. The lead clinical candidate GT-02287 completed a Phase 1 study (n=72) that was reported as safe and generally well tolerated, supporting further development.
Gain Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Current Report. The filing also references an Interactive Data File as Exhibit 104.
The registrant indicates it is an emerging growth company and its common stock trades under GANX on The NASDAQ Stock Market. The company states the press release and related information are furnished and therefore are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except by specific reference. This 8-K does not include the financial statements or numeric results within its text.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing the award of a stock option to director Khalid Islam on 06/24/2025. The option covers 15,000 shares of common stock at an exercise price of $1.79 per share and expires on 06/24/2035. According to the filing, the grant will vest in 12 equal monthly installments beginning 07/24/2025, contingent upon Mr. Islam’s continued service with the company. Following the grant, Mr. Islam beneficially owns 15,000 derivative securities directly. No non-derivative share transactions were reported.
The filing is routine and reflects a standard equity-based compensation mechanism used to align director incentives with shareholder interests. No changes to ownership structure, sales of shares, or additional material financial data were included.
Key take-away: On 06/24/2025 Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Claude Nicaise received a stock option covering 15,000 shares of common stock at an exercise price of $1.79 per share, expiring on 06/24/2035.
The option was awarded, not exercised, and therefore does not immediately affect the public float. Vesting occurs in 12 equal monthly tranches starting 07/24/2025, contingent on Mr. Nicaise’s continued service. After the grant, the director directly holds 15,000 derivative securities; no non-derivative holdings or sales were reported.
This represents routine equity compensation aimed at further aligning board incentives with shareholder interests. No cash changed hands and no other material transactions were disclosed in this filing.
Key take-away: Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Jeffrey Scott Riley received a grant of 15,000 stock options on 06/24/2025.
The option has an exercise price of $1.79 per share and expires on 06/24/2035. The transaction is coded “A” (acquisition) and represents the only derivative security currently reported for the director; no common shares were bought or sold.
Vesting schedule: the award vests in 12 equal monthly installments beginning 07/24/2025, provided Mr. Riley continues his service. Following the grant he beneficially owns 15,000 options, classified as direct ownership. No indirect holdings or Rule 10b5-1 trading plan were indicated.
Investor relevance: This filing reflects standard director compensation and does not involve open-market buying or selling. While the grant modestly increases potential future dilution, its size is immaterial relative to GANX’s total shares outstanding. The filing may signal management’s effort to align director incentives with shareholder value but is unlikely to move the stock on its own.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing a routine equity award to director Eric I. Richman. On 06/24/2025 the director received 15,000 stock options with an exercise price of $1.79 per share.
The options vest in 12 equal monthly installments beginning 07/24/2025, contingent on continued board service, and expire on 06/24/2035. Following the grant, Richman beneficially owns 15,000 derivative securities, all held directly. No shares of common stock were bought or sold, and no other transactions were reported.
FAQ
What is the current stock price of Gain Therapeutics (GANX)?
What is the market cap of Gain Therapeutics (GANX)?
